Urine bactericidal activity against resistant Escherichia coli in an in vitro pharmacodynamic model simulating urine concentrations obtained after 2000/125 mg sustained-release co-amoxiclav and 400 mg norfloxacin administration

Journal of Antimicrobial Chemotherapy

Volumn 57, Issue 4, 2006, Pages 714-719

  Alou, Luis ^a   Aguilar, Lorenzo ^a   Sevillano, David ^a   Giménez, María José ^a   Cafini, Fabio ^a   Valero, Eva ^a   Relaño, María Teresa ^a   Prieto, José ^a  

^a SCHOOL OF MEDICINE   (Spain)

Author keywords

Amoxicillin; Clavulanic acid; E. coli; Pharmacodynamic modelling; Urine bactericidal activity

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE; CLAVULANIC ACID; NORFLOXACIN;

ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM COLONY; BACTERIUM ISOLATE; CALCULATION; CONTROLLED STUDY; CYSTITIS; DRUG EXPOSURE; DRUG RESISTANCE; DRUG URINE LEVEL; ESCHERICHIA COLI; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; SAMPLING; SIMULATION; SINGLE DRUG DOSE; SUSTAINED DRUG RELEASE;

AMOXICILLIN-POTASSIUM CLAVULANATE COMBINATION; ANTI-BACTERIAL AGENTS; CYSTITIS; DELAYED-ACTION PREPARATIONS; ESCHERICHIA COLI; HUMANS; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; NORFLOXACIN; URINE;

EID: 33645128206     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl041     Document Type: Article

References (29)

1. Reynolds R, Potz N, Colman M et al. Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: The BSAC Bacteraemia Resistance Surveillance Programme. J Antimicrob Chemother 2004; 53: 1018-32.
2. Alonso Sanz M, Abad Bécquer MI. Fenotipos de resistencia en aislamientos urinarios de Escherichia coli en la comunidad: implicaciones terapéuticas. Med Clin (Barc) 2003; 120: 361-4.
3. Andreu A, Alos JI, Gobernado M et al. Etiología y sensibilidad a los antimicrobianos delos uropatógenos causantes de la infección urinaria baja adquirida en la comunidad. Estudio nacional multicéntrico. Enferm Infecc Microbiol Clín 2005; 23: 4-9.
4. Simpson I, Durodie J, Knott S et al. Effects of following National Committee for Clinical Laboratory Standards and Deutsche Industrie Norm-Medizinische Mikrobiologie guidelines, country of isolate origin, and site of infection on susceptibility of Escherichia coli to co-amoxiclav (Augmentin). J Clin Microbiol 1998; 36: 1361-5.
5. Garau J, Xercavins M, Rodriguez-Carballeira M et al. Emergence and dissemination of quinolone-resistant Escherichia coli in the community. Antimicrob Agents Chemother 1999; 43: 2736-41.
6. Kaye CM, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced formulation of amoxicillin/ clavulanate. Clin Ther 2001; 23: 578-84.
7. Alou L, Aguilar L, Sevillano D et al. Effect of opsonophagocytosis mediated by specific antibodies on the co-amoxiclav serum bactericidal activity against Streptococcus pneumoniae after administration of a single oral dose of pharmacokinetically enhanced 2000/125 mg co-amoxiclav to healthy volunteers. J Antimicrob Chemother 2005; 55: 742-7.
8. Sevillano D, Calvo A, Gimenez MJ et al. Bactericidal activity of amoxicillin against non-susceptible Streptococcus pneumoniae in an in vitro pharmacodynamic model simulating the concentrations obtained with the 2000/125 mg sustained-release co-amoxiclav formulation. J Antimicrob Chemother 2004; 54: 1148-51.
9. Ponte C, Gracia M, Giménez MJ et al. Urinary concentrations and bactericidal activity against amoxicillin-nonsusceptible strains of Escherichia coli with single-dose, oral, sustained-release amoxicillin/ clavulanic acid: A phase I, open-label, noncomparative clinical trial in healthy volunteers. Clin Ther 2005; 27: 1043-9.
10. Bronner S, Murbach V, Peter JD et al. Ex vivo pharmacodynamics of co-amoxiclav against β-lactamase-producing Escherichia coli in a yucatan miniature pig model that mimics human pharmacokinetics. Antimicrob Agents Chemother 2002; 46: 3782-9.
11. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Sixth Edition: Approved Standard M7-A6. NCCLS, Wayne, PA, USA, 2003.
12. Rodriguez-Baño J, Navarro MD, Romero L et al. Epidemiology and clinical features of infections caused by extended-spectrum β-lactamase-producing Escherichia coli in nonhospitalized patients. J Clin Microbiol 2004; 42: 1089-94.
13. Aguilar L, Balcabao IP, Salva P et al. Ex vivo antibacterial properties of rufloxacin compared with those of norfloxacin in a study with healthy volunteers. Antimicrob Agents Chemother 1996; 40: 17-21.
14. Andrews JM. Microbiological assays. In: Reeves DS, Wise R, Andrews JM et al., eds. Clinical Antimicrobial Assays, 1st edn. Oxford: Oxford University Press, 1999; 35-44.
15. Clinical Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing: Fifteenth Informational Supplement M100-S15. CLSI, Wayne, PA, USA, 2005.
16. Junquera S, Loza E, Baquero F. Evolución del patrón de sensibilidad de aislados de Escherichia coli en urocultivos procedentes del medio hospitalario y extrahospitalario. Enferm Infecc Microbiol Clin 2005; 23: 197-201.
17. Karlowsky JA, Kelly LJ, Thornsberry C et al. Trends in antimicrobial resistance among urinary tract infection isolates of Escherichia coli from female outpatients in the United States. Antimicrob Agents Chemother 2002; 46: 2540-5.
18. Stapleton P, Wu PJ, King A et al. Incidence and mechanisms of resistance to the combination of amoxicillin and clavulanic acid in Escherichia coli. Antimicrob Agents Chemother 1995; 39: 2478-83.
19. Tice AD. Short-course therapy of acute cystitis: A brief review of therapeutic strategies. J Antimicrob Chemother 1999; 43 Suppl A: 85-93.
20. Del Rio G, Dalet F, Aguilar L et al. Single-dose rufloxacin versus 3-day norfloxacin treatment of uncomplicated cystitis: Clinical evaluation and pharmacodynamic considerations Antimicrob Agents Chemother 1996, 40: 408-12.
21. Bedenic B, Vranes J, Suto S et al. Bactericidal activity of oral β-lactam antibiotics in plasma and urine versus isogenic Escherichia coli strains producing broad- and extended-spectrum β-lactamases. Int J Antimicrob Agents 2005; 25: 479-87.
22. Greenwood D, O'Grady F. The comparative performance of β-lactam antibiotics against ampicillin sensitive Escherichia coli in conditions simulating those of the infected urinary bladder. Br J Exp Pathol 1974; 55: 245-50.
23. Anderson JD. Relevance of urinary bladder models to clinical problems and to antibiotic evaluation. J Antimicrob Chemother 1985; 15 Suppl A: 111-5.
24. Anderson JD, Eftekhar F, Cleeland R et al. Comparative activity of mecillinam and ampicillin singly and in combination in the urinary bladder model and experimental mouse model. J Antimicrob Chemother 1981; 8: 121-31.
25. Anderson JD, Johnson KR, Aird MY. Comparison of amoxicillin and ampicillin activities in a continuous culture model of the human urinary bladder. Antimicrob Agents Chemother 1980; 17: 554-7.
26. Gupta K, Hooton TM, Stamm WE. Isolation of fluoroquinolone-resistant rectal Escherichia coli after treatment of acute uncomplicated cystitis. J Antimicrob Chemother 2005; 56: 243-6.
27. Gracia M, Ponte C, Soriano F. Optimal co-amoxiclav ratios for inhibiting Escherichia coli strains with different susceptibility to the compounds. Int J Antimicrob Agents 2005; 25: 352-3.
28. Bertrand X, Talon D. In vitro activity of co-amoxiclav acid against clinical isolates of Escherichia coli. J Antimicrob Chemother 2001; 47: 725-6.
29. Miro E, del Cuerpo M, Navarro F et al. Emergence of clinical Escherichia coli isolates with decreased susceptibility to ceftazidime and synergic effect with co-amoxiclav due to SHV-1 hyperproduction. J Antimicrob Chemother 1998; 42: 535-8.